Imcyse SA Alternatives & Competitors
12 companies similar to Imcyse SA — Pioneering the development of Imotopes™ to prevent, stop and potentially cure au...
Companies similar to Imcyse SA
RHEACELL GmbH & Co. KG
Innovative Stem Cell Therapies Experts from Heidelberg, Germany
Heidelberg, Germany
Fate Therapeutics Inc.
Transforming the lives of patients with autoimmune diseases and cancer.
San Diego, United States
Repertoire Immune Medicines
Repertoire is a biotechnology company creating a new category of immune medicines for canc...
Cambridge, United States
Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunother...
Oxford, United Kingdom
Rival Readout
Competing with Imcyse SA? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
SAB BIO
Working to transform treatment for people living with type 1 diabetes through a unique dis...
Miami, United States
The Woodlands, United Sta...
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Irvine, United States
Rocket Pharmaceuticals
Seeking gene therapy cures
Cranbury, United States
China
SOTIO Biotech
Shaping the future of cancer immunotherapies by translating compelling science into patien...
Prague, Czech Republic
Cabaletta Bio
Engineered T cell therapies designed for the treatment of patients with autoimmune disease...
Philadelphia, United Stat...
About Imcyse SA
Imcyse SA, headquartered in Belgium, is a pioneering player in the biopharmaceutical sector, advancing a novel class of immunotherapies to combat severe autoimmune diseases. Founded in 2011 as a spin-off from the Catholic University of Leuven (KULeuven), the company has carved a niche with its cutting-edge Imotope™ tec...
Development of immunotherapies, Clinical trials for autoimmune diseases, Partnership-driven commercialization
Patients with autoimmune diseases, Healthcare institutions, Pharmaceutical partners, Academic researchers
Autoimmune Diseases, Active Specific Immunotherapy, Imotopes™, Type 1 Diabetes, Immunotherapies, Cytolytic CD4 T-cells, Antigen-Presenting Cells, Synthetic Peptides, Biopharmaceuticals, Clinical Trials, Multiple Sclerosis, Intellectual Property, Imcyse Technology Platform, Chronic Autoimmune Diseases
B2B, B2D
Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Imcyse SA: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Imcyse SA on 23 Feb 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
